Nov 23, 2021 / 01:00PM GMT
Operator
Welcome to the Transgene Conference Call. Please note this conference is being recorded. (Operator Instructions). I will now hand over to your host, Lucie Larguier, Head of Investor Relations, to begin today's conference. Thank you.
Lucie Larguier - Transgene SA - Director of Corporate Communications & IR
Thank you. Hello, everyone. I'm Lucie Larguier, Director of Investor Relations at Transgene. So today, we're going to present the first positive results of the clinical trials evaluating TG4050, our individualized cancer immunotherapy.
With me today are Hedi Ben Brahim, CEO of Transgene; Eric Quemeneur, Chief Scientific Officer; Maud Brandely, Chief Medical Officer; and Kaidre Bendjama, Director Next-Generation Vaccine.
We are honored to be joined by Prof. Christian Ottensmeier, MD, PhD, who is the Professor of Immuno-Oncology at the University of Liverpool and the Global Coordinator of the Head and Neck Trials, currently evaluating TG4050.
I remind you that today's discussion contains forward-looking statements, which are
Transgene SA TG4050 Phase I Studies Results Webcast Transcript
Mar 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers